The Foundation for Angelman Syndrome Therapeutics (FAST) announced today that the non-profit organization has entered into an exclusive global collaborative research and development agreement with the ...
ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that ...
October 17, 2023—The Foundation for Angelman Syndrome Therapeutics (FAST) announced today that the non-profit organization has entered into an exclusive global collaborative research and development ...
NOVATO, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE) today announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its investigational antisense ...
AUSTIN, Texas, June 4, 2024 /PRNewswire/ — The Foundation for Angelman Syndrome Therapeutics (FAST) announced the establishment of an associated drug development accelerator called AS2Bio Inc. The ...
Ultragenyx (RARE) Pharmaceutical announced that the first patient has been dosed in the pivotal Phase 3 Aspire study, NCT06617429, evaluating the efficacy and safety of GTX-102, its investigational ...
Ultragenyx Pharmaceutical Inc. announced the dosing of the first patient in its Phase 3 Aspire study, which is investigating the safety and efficacy of GTX-102, an investigational antisense ...
Families of children with rare diseases will often start non-profit organizations to raise money for early-stage research on their child's condition. Fewer of those organizations start their own ...
9don MSN
Mum's powerful diary entry shows challenges and cherished moments of life with disabled child
Sarah Washbrook's son Ivor has a condition which leaves children significantly intellectually disabled and with balance and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results